埃里奥素B通过通过JAK2/STAT1信号来限制M1巨细胞两极分化,改善了类似克罗恩病的结肠炎
Yang Cheng1, Jing Li2, Lian Wang3
1Department of Blood Transfusion, First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
European journal of pharmacology
|June 30, 2023
概括
埃里奥卡利辛B (EriB) 通过通过JAK2/STAT1通路抑制M1巨分化,减少克罗恩病 (CD) 模型中的炎症,为CD提供潜在的新疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 巨细胞M1极化是克罗恩病 (CD) 炎症的关键.
- 埃里奥卡利辛B (EriB) 是一种具有抗炎性能的天然化合物.
研究的目的:
- 为了研究EriB对小鼠CD型结肠炎的治疗效果.
- 阐明EriB对巨细胞极化作用的基础机制.
主要方法:
- 使用TNBS和Il-10淘汰赛小鼠模型进行CD.
- 通过疾病活性指数,体重变化,组织学和流动细胞计量来评估治疗效果.
- 研究了EriB对M1/M2巨细胞两极分化在体外和体内的影响,探索了JAK2/STAT1通路.
主要成果:
- 治疗EriB改善了结肠炎症状,减轻了体重减轻和疾病得分.
- 埃里B抑制了M1巨细胞极化和促炎性细胞因子的释放 (IL-1β,TNF-α,IL-6).
- EriB 抑制了 JAK2/STAT1 信号通路.
结论:
- 通过通过JAK2/STAT1通路抑制M1巨分化,EriB可以改善小鼠的结肠炎.
- EriB为临床CD治疗提出了一个潜在的治疗策略.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
156
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
156
Drugs for Treatment of Ulcerative Colitis in IBD
175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
200
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
200
Inflammatory Bowel Disease II: Crohn's Disease
299
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
299
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
175
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
175


